Assessment of HER2 status in breast cancer

被引：0
作者：
Penault-Llorca, F [1 ]
Cayre, A [1 ]
机构：
[1] Ctr Jean Perrin, Dept Pathol, F-63011 Clermont Ferrand, France
来源：
BULLETIN DU CANCER | 2004年 / 91卷
关键词：
breast cancer; HER2; immunohistochemistry; in situ hybridization; quality assurance;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
HER2-positive status is the sole criterion for identifying patients with breast cancer for Herceptin(R) (trastuzumab) therapy. Accurate assessment of HER2 status is essential to ensure that all patients who way benefit from Herceptin(R) are correctly identified. There are several assays available to determine HER2 status: the most common in routine clinical practice are immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). The pros and cons of those two tests and the other upcoming methods for assessing HER2 status (with a focus on chromogenic in situ hybridization CISH recently approved by European Commission) tire described in this manuscript. The importance of adhesion to quality assurance programs is underlined. Finally. the different national testing guidelines are discussed.
引用
收藏
页码：S211 / S215
页数：5
相关论文
共 34 条
[1]   Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer [J].
Arnould, L ;
Denoux, Y ;
MacGrogan, G ;
Penault-Llorca, F ;
Fiche, M ;
Treilleux, I ;
Mathieu, MC ;
Vincent-Salomon, A ;
Vilain, MO ;
Couturier, J .
BRITISH JOURNAL OF CANCER, 2003, 88 (10) :1587-1591
[2]   The clinical evaluation of HER-2 status: which test to use? [J].
Bartlett, J ;
Mallon, E ;
Cooke, T .
JOURNAL OF PATHOLOGY, 2003, 199 (04) :411-417
[3]   Current perspectives on HER2 testing:: A review of national testing guidelines [J].
Bilous, M ;
Dowsett, M ;
Hanna, W ;
Isola, J ;
Lebeau, A ;
Moreno, A ;
Penault-Llorca, F ;
Rüschoff, J ;
Tomasic, G ;
de Vijver, MV .
MODERN PATHOLOGY, 2003, 16 (02) :173-182
[4]  
Birner P, 2001, CLIN CANCER RES, V7, P1669
[5]  
Campone M, 2003, B CANCER, V90, P614
[6]   Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma [J].
Couturier, J ;
Vincent-Salomon, A ;
Nicolas, A ;
Beuzeboc, P ;
Mouret, E ;
Zafrani, B ;
Sastre-Garau, X .
MODERN PATHOLOGY, 2000, 13 (11) :1238-1243
[7]  
Denoux Y, 2003, ANN PATHOL, V23, P617
[8]   Current status of HER2 testing [J].
Di Leo, A ;
Dowsett, M ;
Horten, B ;
Penault-Llorca, F .
ONCOLOGY, 2002, 63 :25-32
[9]  
Diaz N M, 2001, Cancer Control, V8, P415
[10]   Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres [J].
Dowsett, M ;
Bartlett, J ;
Ellis, IO ;
Salter, J ;
Hills, M ;
Mallon, E ;
Watters, AD ;
Cooke, T ;
Paish, C ;
Wencyk, PM ;
Pinder, SE .
JOURNAL OF PATHOLOGY, 2003, 199 (04) :418-423
1234